Are you Dr. Rodig?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 37 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
75 Francis St
Brigham & Women's Hospital, Dept. Of Pathology, Amory 3
Boston, MA 02115Phone+1 617-732-7510- Is this information wrong?
Summary
- Dr. Scott Rodig, MD is a board certified pathologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Brigham and Women's Hospital and is an Associate Professor at Harvard Medical School.
Education & Training
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1998 - 2002
Washington University in St. Louis School of MedicineClass of 1998
Certifications & Licensure
MA State Medical License 2002 - 2025- American Board of Pathology Anatomic Pathology
- American Board of Pathology Hematology
Clinical Trials
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors Start of enrollment: 2011 Nov 01
- Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2013 Aug 28
Publications & Presentations
PubMed
- Graph Fourier transform for spatial omics representation and analyses of complex organs.Yuzhou Chang, Jixin Liu, Yi Jiang, Anjun Ma, Yao Yu Yeo, Qi Guo, Megan McNutt, Jordan Krull, Scott J Rodig, Dan H Barouch, Garry Nolan, Dong Xu, Sizun Jiang, Zihai Li,...> ;Research Square. 2024 Feb 15
- Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.Huffman, B., Singh, H., Ali, L., Horick, N., Wang, S., Hoffman, M., Metayer, K., Murray, S., Bird, A., Abrams, T., Biller, L., Chan, J., Meyerhardt, J., McCleary, N., ...> ;Journal for Immunotherapy of Cancer. 2024 Jan 25
- A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity.Patel, A., Ashenberg, O., Collins, N., Segerstolpe, Å., Jiang, S., Slyper, M., Huang, X., Caraccio, C., Jin, H., Sheppard, H., Xu, K., Chang, T., Orr, B., Shirinifard,...> ;Biorxiv. 2024 Jan 16
- Join now to see all
Press Mentions
New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP ComboMarch 19th, 2020
Research Update: Biomarkers as Predictors of Immunotherapy Response in MelanomaSeptember 13th, 2018
Study Finds Melanoma Biomarkers Predicting Checkpoint Blocker ResponseJuly 18th, 2018- Join now to see all
Hospital Affiliations
Brigham and Women's HospitalBoston, Massachusetts
